NKTX
Nkarta, Inc.
$1.79
+2.87%
2026-10-23
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Key Fundamentals
Forward P/E
-1.57
EPS (TTM)
$-1.59
ROE
-38.8%
Profit Margin
0.0%
Debt/Equity
29.68
Price/Book
0.80
Beta
0.97
Market Cap
$197.0M
Avg Volume (10D)
624K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$3.30
60D Low
$1.66
Avg Volume
689K
Latest Close
$1.79
Get breakout alerts for NKTX
Sign up for Breakout Scanner to receive daily notifications when NKTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Nkarta, Inc. (NKTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors NKTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. NKTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.